Compile Data Set for Download or QSAR
maximum 50k data
Found 30 Enz. Inhib. hit(s) with all data for entry = 5982
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103469(US8552004, 2.07)
Affinity DataIC50:  2.58nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103481(US8552004, 2.08)
Affinity DataIC50:  2.76nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM60432(BDBM50468001 | US11236089, Compound AZD-6738 | US8...)
Affinity DataIC50:  3.75nMpH: 7.4 T: 2°CAssay Description:ATR for use in the in vitro enzyme assay was obtained from HeLa nuclear extract (CIL Biotech, Mons, Belgium) by immunoprecipitation with rabbit polyc...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103467(US8552004, 2.03)
Affinity DataIC50:  5.61nMpH: 7.4 T: 2°CAssay Description:ATR for use in the in vitro enzyme assay was obtained from HeLa nuclear extract (CIL Biotech, Mons, Belgium) by immunoprecipitation with rabbit polyc...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103467(US8552004, 2.03)
Affinity DataIC50:  7.05nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103483(US8552004, 3.02)
Affinity DataIC50:  8.43nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103490(US8552004, 5.09)
Affinity DataIC50:  10.1nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103472(US8552004, 3.01 | US8552004, 3.02)
Affinity DataIC50:  12.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103480(US8552004, 2.06)
Affinity DataIC50:  12.9nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103471(BDBM50456371 | US8552004, 2.11)
Affinity DataIC50:  13.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103488(US8552004, 5.04)
Affinity DataIC50:  16.2nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103491(US8552004, 5.08)
Affinity DataIC50:  18.0nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103487(US8552004, 5.05)
Affinity DataIC50:  18.3nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103466(US8552004, 2.04)
Affinity DataIC50:  21.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103477(US8552004, 5.07)
Affinity DataIC50:  29.0nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103476(US8552004, 5.03)
Affinity DataIC50:  33.1nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103465(US8552004, 1.01)
Affinity DataIC50:  34.0nMpH: 7.4 T: 2°CAssay Description:ATR for use in the in vitro enzyme assay was obtained from HeLa nuclear extract (CIL Biotech, Mons, Belgium) by immunoprecipitation with rabbit polyc...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103484(US8552004, 4.02)
Affinity DataIC50:  39.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103486(US8552004, 5.06)
Affinity DataIC50:  44.4nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103489(US8552004, 5.10)
Affinity DataIC50:  47.0nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103474(US8552004, 4.03)
Affinity DataIC50:  51.1nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103473(US8552004, 4.01)
Affinity DataIC50:  53.6nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM60432(BDBM50468001 | US11236089, Compound AZD-6738 | US8...)
Affinity DataIC50:  58.3nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103475(US8552004, 5.01)
Affinity DataIC50:  62.5nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103485(US8552004, 5.02)
Affinity DataIC50:  70.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103468(US8552004, 2.05)
Affinity DataIC50:  75.8nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103482(US8552004, 2.10)
Affinity DataIC50:  109nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103470(US8552004, 2.09)
Affinity DataIC50:  159nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM60433(BDBM103466 | US8552004, 2.01)
Affinity DataIC50:  236nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetSerine/threonine-protein kinase ATR(Homo sapiens (Human))
Astrazeneca

US Patent
LigandPNGBDBM103465(US8552004, 1.01)
Affinity DataIC50:  581nMAssay Description:ATM and ATR have distinct and overlapping responses to DNA damage. They must participate together and responses must be co-ordinated. Both pathways...More data for this Ligand-Target Pair
In DepthDetails US Patent